banter and General Discussion, page-9395

First 9395 Last

Share
Profile

Follow
LearningEachDay

5,548 Posts.

2020

07/04/24

13:27

Post #: 73226496
Share

Originally posted by eyeswideopen: ↑

Apologies if this has been posted or discussed previously as I don't have the time to keep up with all the posts here lately. This point in motley fool's advertising, "It points out that the timing of the correspondence coincides with refreshed leadership at the newly formed Office of Therapeutic Products at the FDA." I wasn't aware of this?
Mesoblast Ltd (ASX: MSB)

Another note out of Bell Potter reveals that its analysts have retained their speculative buy rating on this biotechnology company's shares with a significantly improved price target of $1.40 (from 58 cents previously). Bell Potter notes that the FDA has used carefully chosen words to inform Mesoblast that the available clinical data from its Phase 3 study MSB-GvHD001 in children with steroid refractory acute graft versus host disease (SR a GvHD) appears sufficient to support a resubmission of the Biological Licence Application (BLA) for Remestemcel. It points out that the timing of the correspondence coincides with refreshed leadership at the newly formed Office of Therapeutic Products at the FDA. In light of this, the broker has renewed confidence for a prospective approval for Remestemcel later this year. It feels that a first approval may represent a gateway to a series of label expansions in the ensuing period. The Mesoblast share price is fetching 86.7 cents on Friday."

Bold highlight is mine.

Expand

https://www.morganlewis.com/blogs/asprescribed/2023/09/regulatory-spotlight-for-biotech-on-the-horizon-for-cber

MSB Price at posting: 86.5¢ Sentiment: Buy Disclosure: Held
17 Upvote

4 Great analysis

Reply

Top Stories

NIM

Nimy extends sulphide targets at Mons with new anomalies identified

SS1

Sun Silver gets that drill to thrill feeling from high grade hits at Maverick Spring

NXM

Drilling at Bethanga shows signs of Cu-Au porphyry system for Nexus

TBN

Tamboran is developing the NT Beetaloo Basin. To get there, it's listing at $36/sh on the NYSE

SFX

Sheffield Resources achieves milestone production, shipments at Thunderbird, WA

There are more pages in this discussion • 585 more messages in this thread...

First 9395 Last

Add MSB (ASX) to my watchlist

(20min delay)
Last 98.0¢		Change 0.010(1.03%)		Mkt cap ! $1.118B

Open	High	Low	Value	Volume
96.0¢	99.0¢	95.5¢	$5.286M	5.409M

Buyers (Bids)

No.	Vol.	Price($)
3	91218	98.0¢

Sellers (Offers)

Price($)	Vol.	No.
99.0¢	63577	4

View Market Depth

No.	Vol.	Price($)
3	91218	0.980
42	307626	0.975
14	519246	0.970
6	149303	0.965
8	166210	0.960

Price($)	Vol.	No.
0.990	63577	4
0.995	68052	2
1.000	121535	11
1.005	55374	2
1.010	10000	1

Last trade - 16.10pm 27/06/2024 (20 minute delay)

MSB (ASX) Chart

banter and General Discussion, page-9395

Nimy extends sulphide targets at Mons with new anomalies identified

Sun Silver gets that drill to thrill feeling from high grade hits at Maverick Spring

Drilling at Bethanga shows signs of Cu-Au porphyry system for Nexus

Tamboran is developing the NT Beetaloo Basin. To get there, it's listing at $36/sh on the NYSE

Sheffield Resources achieves milestone production, shipments at Thunderbird, WA

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

banter and General Discussion, page-9395

Top Stories

Nimy extends sulphide targets at Mons with new anomalies identified

Sun Silver gets that drill to thrill feeling from high grade hits at Maverick Spring

Drilling at Bethanga shows signs of Cu-Au porphyry system for Nexus

Tamboran is developing the NT Beetaloo Basin. To get there, it's listing at $36/sh on the NYSE

Sheffield Resources achieves milestone production, shipments at Thunderbird, WA

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News